Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:MACK
- CUSIP: 59032810
- Web: www.merrimackpharma.com
Capitalization:- Market Cap: $180.1 million
- Outstanding Shares: 132,741,000
Average Prices:- 50 Day Moving Avg: $1.34
- 200 Day Moving Avg: $2.69
- 52 Week Range: $1.13 - $6.79
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.09
- P/E Growth: -0.43
Sales & Book Value:- Annual Revenue: $144.27 million
- Price / Sales: 1.25
- Book Value: ($2.09) per share
- Price / Book: -0.65
Profitability:- EBIDTA: ($88,040,000.00)
- Net Margins: -105.18%
- Return on Assets: -135.72%
Debt:- Debt-to-Equity Ratio: -0.79%
- Current Ratio: 0.43%
- Quick Ratio: 0.43%
Misc:- Average Volume: 3.03 million shs.
- Beta: 2.03
- Short Ratio: 5.24
Frequently Asked Questions for Merrimack Pharmaceuticals (NASDAQ:MACK)
What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals declared an annual dividend on Friday, April 7th. Stockholders of record on Wednesday, May 17th will be paid a dividend of $1.06 per share on Friday, May 26th. The ex-dividend date is Tuesday, May 30th. View Merrimack Pharmaceuticals' Dividend History.
How were Merrimack Pharmaceuticals' earnings last quarter?
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.15. During the same quarter in the prior year, the business posted ($0.33) earnings per share. View Merrimack Pharmaceuticals' Earnings History.
Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2017?
5 analysts have issued 1-year target prices for Merrimack Pharmaceuticals' shares. Their predictions range from $5.00 to $13.00. On average, they expect Merrimack Pharmaceuticals' share price to reach $8.33 in the next year. View Analyst Ratings for Merrimack Pharmaceuticals.
What are analysts saying about Merrimack Pharmaceuticals stock?
Here are some recent quotes from research analysts about Merrimack Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "With the sale of Onivyde, Merrimack is back to being a development-stage biopharmaceutical company. Thus, the successful development of the three lead candidates in its pipeline is critical for Merrimack’s growth. Moreover, two of the candidates, MM-121 and MM-141, are still being evaluated in phase II studies. And the third candidate, MM-310 entered phase I study in the first quarter of 2017. Also, shares of the company have underperformed the Zacks categorized Medical Biomed/Genetics industry year to date. However, the cash received from Ipsen will be used to pay down the huge debt and return value to shareholders in the form of dividends. Estimates have remained mostly stable lately ahead of the Q2 results. The company has a mixed record of earnings surprises in recent quarters." (7/17/2017)
- 2. J P Morgan Chase & Co analysts commented, "Our view that 2016 consensus estimates, while achievable, are perhaps not meaningfully beatable (and 2017 needs to moderate incrementally, in our view)."Key pipeline catalysts, while underappreciated, are weighted 2Q17+."Our expectation that R&D prioritization and search for a new CEO could take time (currently no timelines outlined)."A continued financing overhang (~12 months of cash)." (10/7/2016)
Are investors shorting Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals saw a increase in short interest in July. As of July 14th, there was short interest totalling 25,683,568 shares, an increase of 2.1% from the June 30th total of 26,222,342 shares. Based on an average trading volume of 1,788,334 shares, the days-to-cover ratio is currently 14.4 days. Currently, 20.5% of the shares of the stock are short sold.
Who are some of Merrimack Pharmaceuticals' key competitors?
Some companies that are related to Merrimack Pharmaceuticals include Concert Pharmaceuticals (CNCE), Celyad SA (CYAD), Novavax (NVAX), Idera Pharmaceuticals (IDRA), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX), Curis (CRIS), Advaxis (ADXS), Codexis (CDXS), Voyager Therapeutics (VYGR), Corvus Pharmaceuticals (CRVS), Horizon Discovery Group PLC (HZD), Zynerba Pharmaceuticals (ZYNE), Protagonist Therapeutics (PTGX), NewLink Genetics Corporation (NLNK), Compugen (CGEN), Arbutus Biopharma Corporation (ABUS) and Asterias Biotherapeutics (AST).
Who are Merrimack Pharmaceuticals' key executives?
Merrimack Pharmaceuticals' management team includes the folowing people:
- Gary L. Crocker, Chairman of the Board
- Richard Peters M.D., Ph.D., President, Chief Executive Officer, Principal Financial Officer, Director
- John L. Green, Chief Accounting Officer, Controller
- Ellen K. Forest, Head of Human Resources
- Sergio L. Santillana, Chief Medical Officer
- Ulrik B. Nielsen Ph.D., Director
- John M. Dineen, Independent Director
- Vivian S. Lee, Independent Director
- John Mendelsohn M.D., Independent Director
- Michael E. Porter Ph.D., Independent Director
Who owns Merrimack Pharmaceuticals stock?
Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Kempner Capital Management Inc. (0.11%), Clear Harbor Asset Management LLC (0.11%) and Creative Planning (0.07%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond, Edward J Stewart, Michael E Porter, Vivian S Lee and William M Mcclements. View Institutional Ownership Trends for Merrimack Pharmaceuticals.
Who bought Merrimack Pharmaceuticals stock? Who is buying Merrimack Pharmaceuticals stock?
Merrimack Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Clear Harbor Asset Management LLC and Creative Planning. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements. View Insider Buying and Selling for Merrimack Pharmaceuticals.
How do I buy Merrimack Pharmaceuticals stock?
Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merrimack Pharmaceuticals' stock price today?
One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $1.36.
MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.20) |
| Consensus Price Target: | $8.33 (512.75% upside) |
Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/19/2017 | Cowen and Company | Reiterated Rating | Market Perform | | Low |  |
| 1/11/2017 | Robert W. Baird | Reiterated Rating | Neutral | $5.00 | N/A | |
| 11/10/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | $7.00 | N/A | |
| 11/10/2016 | BTIG Research | Reiterated Rating | Neutral | | N/A | |
| 8/5/2016 | Brean Capital | Set Price Target | Buy | $16.00 -> $13.00 | N/A | |
| 5/20/2016 | Mizuho | Reiterated Rating | Buy | $13.00 | N/A | |
| 12/30/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | | N/A | |
| 8/11/2015 | Cantor Fitzgerald | Reiterated Rating | Buy | $16.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)Earnings History by Quarter for Merrimack Pharmaceuticals (NASDAQ MACK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | ($0.07) | ($0.22) | $32.16 million | | View | N/A | |
| 3/1/2017 | Q416 | ($0.21) | ($0.25) | $50.44 million | $61.20 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.27) | ($0.23) | $41.00 million | $28.07 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.33) | ($0.40) | $33.35 million | $33.70 million | View | N/A | |
| 5/2/2016 | Q116 | ($0.38) | ($0.33) | $24.16 million | $21.30 million | View | N/A | |
| 2/25/2016 | Q415 | ($0.41) | ($0.41) | $31.73 million | $21.42 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.40) | ($0.38) | $14.04 million | $16.44 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.31) | ($0.21) | $17.57 million | $36.60 million | View | Listen | |
| 5/7/2015 | Q1 2015 | ($0.30) | ($0.32) | $14.50 million | $14.84 million | View | N/A | |
| 2/26/2015 | Q4 | ($0.23) | ($0.09) | $25.13 million | $33.91 million | View | N/A | |
| 11/10/2014 | Q3 2014 | ($0.12) | ($0.27) | $61.50 million | $28.00 million | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.32) | ($0.17) | $10.83 million | $27.82 million | View | N/A | |
| 5/1/2014 | Q114 | ($0.31) | ($0.27) | $11.93 million | $13.03 million | View | N/A | |
| 2/27/2014 | | ($0.29) | ($0.33) | | | View | N/A | |
| 11/7/2013 | | ($0.34) | ($0.39) | | | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.28) | ($0.31) | $13.68 million | $18.45 million | View | N/A | |
| 3/14/2013 | Q4 2012 | ($0.26) | ($1.76) | $11.77 million | $12.58 million | View | N/A | |
| 11/14/2012 | Q312 | | ($1.81) | $8.60 million | $11.30 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.65 EPS
Dividend History by Quarter for Merrimack Pharmaceuticals (NASDAQ MACK)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 4/7/2017 | Annual | $1.06 | | 5/30/2017 | 5/17/2017 | 5/26/2017 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Merrimack Pharmaceuticals (NASDAQ:MACK)Insider Ownership Percentage: 8.53%
Institutional Ownership Percentage: 59.22%
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/12/2017 | Daryl C Drummond | Insider | Sell | 4,097 | $3.72 | $15,240.84 | |
| 7/25/2016 | Birgit M Schoeberl | Insider | Sell | 50,000 | $5.50 | $275,000.00 | |
| 3/17/2016 | Michael E Porter | Director | Buy | 5,000 | $7.20 | $36,000.00 | |
| 3/15/2016 | Michael E Porter | Director | Buy | 5,000 | $7.65 | $38,250.00 | |
| 3/8/2016 | Michael E Porter | Director | Buy | 10,000 | $7.09 | $70,900.00 | |
| 3/3/2016 | Michael E Porter | Director | Buy | 15,000 | $6.39 | $95,850.00 | |
| 3/1/2016 | Michael E Porter | Director | Buy | 20,000 | $6.11 | $122,200.00 | |
| 2/29/2016 | Vivian S Lee | Director | Buy | 35,000 | $5.50 | $192,500.00 | |
| 2/29/2016 | William M Mcclements | Insider | Buy | 2,000 | $5.72 | $11,440.00 | |
| 1/5/2016 | Edward J. Stewart | insider | Sell | 4,000 | $8.00 | $32,000.00 | |
| 12/1/2015 | Edward J. Stewart | insider | Sell | 5,000 | $9.33 | $46,650.00 | |
| 11/2/2015 | Edward J. Stewart | insider | Sell | 6,000 | $9.42 | $56,520.00 | |
| 10/16/2015 | Edward J. Stewart | insider | Sell | 1,000 | $10.00 | $10,000.00 | |
| 10/2/2015 | Edward J. Stewart | insider | Sell | 5,000 | $8.20 | $41,000.00 | |
| 9/1/2015 | Edward J. Stewart | insider | Sell | 6,000 | $9.88 | $59,280.00 | |
| 8/21/2015 | Michael E Porter | Director | Buy | 5,000 | $9.76 | $48,800.00 | |
| 8/17/2015 | Edward J. Stewart | insider | Sell | 6,000 | $10.49 | $62,940.00 | |
| 8/14/2015 | Michael E Porter | Director | Buy | 13,000 | $10.54 | $137,020.00 | |
| 7/20/2015 | Ulrik B Nielsen | Director | Sell | 20,000 | $10.71 | $214,200.00 | |
| 7/15/2015 | Edward J Stewart | Insider | Sell | 6,000 | $11.84 | $71,040.00 | |
| 7/15/2015 | William A Sullivan | CFO | Sell | 15,000 | $11.85 | $177,750.00 | |
| 6/19/2015 | Ulrik B Nielsen | Director | Sell | 40,000 | $12.02 | $480,800.00 | |
| 6/18/2015 | Edward J Stewart | Insider | Sell | 2,000 | $12.00 | $24,000.00 | |
| 6/15/2015 | Edward J Stewart | Insider | Sell | 6,000 | $10.67 | $64,020.00 | |
| 6/15/2015 | William A Sullivan | CFO | Sell | 15,000 | $10.65 | $159,750.00 | |
| 5/19/2015 | Ulrik B Nielsen | Director | Sell | 40,000 | $13.04 | $521,600.00 | |
| 5/13/2015 | Michael E Porter | Director | Buy | 8,284 | $11.79 | $97,668.36 | |
| 4/20/2015 | Ulrik B Nielsen | Director | Sell | 40,000 | $12.88 | $515,200.00 | |
| 4/15/2015 | Edward J Stewart | SVP | Sell | 8,000 | $12.79 | $102,320.00 | |
| 4/15/2015 | William A Sullivan | CFO | Sell | 15,000 | $12.87 | $193,050.00 | |
| 4/13/2015 | Gordon J Fehr | Director | Sell | 20,000 | $13.00 | $260,000.00 | |
| 3/24/2015 | Robert J Mulroy | CEO | Sell | 114,368 | $11.71 | $1,339,249.28 | |
| 3/23/2015 | Robert J Mulroy | CEO | Sell | 10,400 | $11.69 | $121,576.00 | |
| 3/20/2015 | Michael E Porter | Director | Buy | 5,000 | $11.77 | $58,850.00 | |
| 3/19/2015 | Ulrik B Nielsen | Director | Sell | 40,000 | $11.97 | $478,800.00 | |
| 3/19/2015 | William A Sullivan | CFO | Sell | 15,000 | $11.97 | $179,550.00 | |
| 3/17/2015 | Birgit M Schoeberl | Insider | Sell | 42,234 | $12.00 | $506,808.00 | |
| 3/17/2015 | Edward J Stewart | SVP | Sell | 8,000 | $11.95 | $95,600.00 | |
| 3/17/2015 | Michael E Porter | Director | Buy | 1,190 | $11.77 | $14,006.30 | |
| 3/16/2015 | Birgit M Schoeberl | Insider | Sell | 20,897 | $12.00 | $250,764.00 | |
| 3/16/2015 | Edward J Stewart | SVP | Sell | 6,000 | $11.93 | $71,580.00 | |
| 3/11/2015 | Michael E Porter | Director | Buy | 5,000 | $11.33 | $56,650.00 | |
| 3/2/2015 | Michael E Porter | Director | Buy | 5,000 | $10.93 | $54,650.00 | |
| 2/23/2015 | Ulrik B Nielsen | Director | Sell | 20,000 | $10.91 | $218,200.00 | |
| 2/20/2015 | Robert J Mulroy | CEO | Sell | 150,000 | $10.94 | $1,641,000.00 | |
| 1/15/2015 | Edward J Stewart | SVP | Sell | 6,000 | $11.19 | $67,140.00 | |
| 12/24/2014 | William A Sullivan | CFO | Sell | 15,000 | $10.70 | $160,500.00 | |
| 12/23/2014 | Vivian S Lee | Director | Buy | 20,000 | $10.23 | $204,600.00 | |
| 12/18/2014 | Anthony J Sinskey | Director | Sell | 20,000 | $10.31 | $206,200.00 | |
| 12/15/2014 | Edward J Stewart | SVP | Sell | 6,000 | $10.63 | $63,780.00 | |
| 12/8/2014 | Robert J Mulroy | CEO | Sell | 200,000 | $9.84 | $1,968,000.00 | |
| 12/2/2014 | Michael E Porter | Director | Buy | 8,000 | $8.71 | $69,680.00 | |
| 11/21/2014 | Michael E Porter | Director | Buy | 11,909 | $8.87 | $105,632.83 | |
| 11/18/2014 | Edward J Stewart | SVP | Sell | 5,000 | $8.55 | $42,750.00 | |
| 11/14/2014 | Michael E Porter | Director | Buy | 5,000 | $8.29 | $41,450.00 | |
| 11/13/2014 | Gary L Crocker | Director | Buy | 14,390 | $8.47 | $121,883.30 | |
| 11/12/2014 | Michael E Porter | Director | Buy | 40,000 | $8.37 | $334,800.00 | |
| 10/23/2014 | Edward J Stewart | SVP | Sell | 3,000 | $9.05 | $27,150.00 | |
| 9/30/2014 | William A Sullivan | CFO | Sell | 105,282 | $8.61 | $906,478.02 | |
| 9/29/2014 | William A Sullivan | CFO | Sell | 64,404 | $8.40 | $540,993.60 | |
| 9/24/2014 | Edward J Stewart | SVP | Sell | 12,000 | $8.22 | $98,640.00 | |
| 6/23/2014 | Gary L Crocker | Director | Buy | 36,000 | $6.84 | $246,240.00 | |
| 5/20/2014 | Gary Crocker | Director | Buy | 4,000 | $6.69 | $26,760.00 | |
| 5/19/2014 | Gary Crocker | Director | Buy | 9,400 | $6.68 | $62,792.00 | |
| 5/16/2014 | Michael Porter | Director | Buy | 15,000 | $6.49 | $97,350.00 | |
| 5/13/2014 | Anthony Sinskey | Director | Buy | 5,000 | $6.74 | $33,700.00 | |
| 5/8/2014 | Michael Porter | Director | Buy | 10,000 | $6.59 | $65,900.00 | |
| 5/7/2014 | Gary Crocker | Director | Buy | 4,400 | $6.77 | $29,788.00 | |
| 5/6/2014 | Gary Crocker | Director | Buy | 17,500 | $6.89 | $120,575.00 | |
| 5/5/2014 | Michael Porter | Director | Buy | 15,000 | $6.41 | $96,150.00 | |
| 5/5/2014 | Robert Mulroy | CEO | Buy | 5,000 | $6.31 | $31,550.00 | |
| 12/17/2013 | Michael Porter | Director | Buy | 25,000 | $4.75 | $118,750.00 | |
| 12/12/2013 | William Mcclements | SVP | Buy | 4,000 | $4.26 | $17,040.00 | |
| 12/10/2013 | Michael Porter | Director | Buy | 18,000 | $4.38 | $78,840.00 | |
| 12/6/2013 | James Quigley | Director | Buy | 39,000 | $4.70 | $183,300.00 | |
| 12/4/2013 | Robert Mulroy | CEO | Buy | 33,100 | $4.42 | $146,302.00 | |
| 12/3/2013 | Sarah Nash | Director | Buy | 47,500 | $4.17 | $198,075.00 | |
| 12/2/2013 | William Mcclements | SVP | Buy | 2,000 | $4.06 | $8,120.00 | |
| 11/29/2013 | Anthony Sinskey | Director | Buy | 3,800 | $3.92 | $14,896.00 | |
| 11/27/2013 | Gary Crocker | Director | Buy | 207,000 | $3.72 | $770,040.00 | |
| 12/14/2012 | John Mendelsohn | Director | Buy | 5,000 | $6.63 | $33,150.00 | |
| 12/13/2012 | Gary L Crocker | Director | Buy | 36,500 | $6.77 | $247,105.00 | |
| 12/10/2012 | Michael E Porter | Director | Buy | 10,000 | $6.08 | $60,800.00 | |
| 9/14/2012 | Gary L Crocker | Director | Buy | 64,800 | $8.33 | $539,784.00 | |
| 8/24/2012 | James H Quigley | Director | Buy | 12,500 | $7.55 | $94,375.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Merrimack Pharmaceuticals (NASDAQ:MACK)
Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
| Source: |
|
| Date | Headline |
|---|
 | Merrimack Appoints Thomas Needham as Chief Business Officer - PR Newswire (press release)
www.prnewswire.com - July 24 at 12:43 PM |
 | Merrimack Appoints Thomas Needham as Chief Business Officer
finance.yahoo.com - July 24 at 12:42 PM |
 | Ex-Akebia Employee Faces Losing Bail in Insider Trading Case - New York Times
www.nytimes.com - July 22 at 6:15 AM |
 | Merrimack Pharmaceuticals, Inc. (MACK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 18 at 3:11 PM |
| Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - July 17 at 2:52 PM |
| Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Short Interest Down 19.9% in June
www.americanbankingnews.com - July 15 at 7:22 AM |
| Zacks Investment Research Downgrades Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) to Sell
www.americanbankingnews.com - July 11 at 4:10 PM |
 | Technical Snapshots for These Biotech Stocks -- Merrimack Pharma, MannKind, GlycoMimetics, and Radius Health
www.bizjournals.com - June 29 at 1:11 AM |
| Technical Snapshots for These Biotech Stocks -- Merrimack Pharma, MannKind, GlycoMimetics, and Radius Health - PR Newswire (press release)
www.prnewswire.com - June 28 at 7:43 AM |
| Short Interest in Merrimack Pharmaceuticals, Inc. (MACK) Rises By 39.7%
www.americanbankingnews.com - June 28 at 7:02 AM |
| Merrimack Pharmaceuticals, Inc. (MACK) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - June 23 at 12:37 PM |
| Key Pharma Stocks With Advanced Developments and Breakthrough Discoveries
www.prnewswire.com - June 21 at 7:30 PM |
 | Merrimack Pharma (MACK) Completes Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
www.streetinsider.com - June 19 at 11:43 AM |
| Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
finance.yahoo.com - June 19 at 11:43 AM |
 | BRIEF-Merrimack Pharmaceuticals says Richard Peters to be principal financial officer - Reuters
www.reuters.com - June 16 at 7:21 PM |
| Why Is Merrimack (MACK) Down 57.6% Since the Last Earnings Report?
finance.yahoo.com - June 14 at 9:55 AM |
| Merrimack Pharmaceuticals Inc (MACK) Short Interest Update
www.americanbankingnews.com - June 11 at 12:46 PM |
| Merrimack Pharma (MACK) Names Sergio Santillana as CMO - StreetInsider.com
www.streetinsider.com - June 8 at 7:21 PM |
| Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources
finance.yahoo.com - June 8 at 10:30 AM |
| Merrimack Pharmaceuticals Inc (MACK) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - June 4 at 8:50 AM |
 | Why Merrimack Pharmaceuticals Stock Is Tanking Today - Motley Fool
www.fool.com - June 1 at 7:14 PM |
| As Merrimack shares hit new low, CEO vows to stay the course - Boston Business Journal
www.bizjournals.com - June 1 at 7:14 PM |
| Why Merrimack Pharmaceuticals Stock Is Tanking Today
www.fool.com - May 31 at 11:25 AM |
| Merrimack Pharmaceuticals Inc (MACK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 29 at 12:47 PM |
 | Merrimack Pharmaceuticals, Inc. (MACK) Ex-Dividend Date Scheduled for May 30, 2017 - Nasdaq
www.nasdaq.com - May 26 at 7:13 PM |
| Merrimack Pharma (MACK) CFO Resigns
www.streetinsider.com - May 26 at 3:36 AM |
| Merrimack Announces Management Change
finance.yahoo.com - May 26 at 3:36 AM |
| Merrimack Pharmaceuticals Inc (mack) to Issue Annual Dividend of $1.06
www.americanbankingnews.com - May 25 at 2:27 PM |
| Merrimack Pharmaceuticals Inc (MACK) Given "Market Perform" Rating at Cowen and Company
www.americanbankingnews.com - May 19 at 10:18 PM |
| Merrimack Pharmaceuticals Inc (MACK) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 12:24 PM |
| Insider Selling: Merrimack Pharmaceuticals Inc (MACK) Insider Sells 4,097 Shares of Stock
www.americanbankingnews.com - May 12 at 8:26 PM |
| Edited Transcript of MACK earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 11 at 6:56 PM |
| Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde
finance.yahoo.com - May 11 at 6:56 PM |
 | BRIEF-Merrimack reports Q1 loss per share $0.23
www.businessinsider.com - May 11 at 4:03 AM |
| Merrimack Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 5:58 PM |
| Merrimack Pharmaceuticals Inc (MACK) Releases Earnings Results, Misses Expectations By $0.11 EPS
www.americanbankingnews.com - May 10 at 3:52 PM |
 | Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss
www.zacks.com - May 10 at 12:41 PM |
| Earnings Reaction History: Merrimack Pharmaceuticals Inc, 36.4% Follow-Through Indicator, 4.2% Sensitive
www.nasdaq.com - May 10 at 12:41 PM |
| Merrimack Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 12:41 PM |
| Investor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 12:41 PM |
| Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss
finance.yahoo.com - May 10 at 12:41 PM |
 | Merrimack reports 1Q loss
marketbeat.com - May 10 at 7:04 AM |
| Merrimack Pharmaceuticals (MACK) Receiving Somewhat Negative Press Coverage, Study Finds
www.americanbankingnews.com - May 3 at 9:48 AM |
| Merrimack Announces Timing of First Quarter 2017 Investor Conference Call - PR Newswire (press release)
www.prnewswire.com - May 3 at 8:20 AM |
| Merrimack Announces Timing of First Quarter 2017 Investor Conference Call
finance.yahoo.com - May 2 at 7:51 PM |
| Merrimack Pharmaceuticals Inc (MACK) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 2 at 2:48 PM |
| Merrimack Pharmaceuticals Inc (MACK) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 2 at 1:56 PM |
| Somewhat Positive Media Coverage Very Unlikely to Impact Merrimack Pharmaceuticals (MACK) Stock Price
www.americanbankingnews.com - April 27 at 11:38 PM |
| What's in the Cards for Merrimack (MACK) in Q1 Earnings?
www.zacks.com - April 27 at 6:57 PM |
| Merrimack Pharmaceuticals (MACK) Getting Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 23 at 8:55 PM |
Merrimack Pharmaceuticals (MACK) Chart for Tuesday, July, 25, 2017
